Surgery Partners, Inc. (SGRY)
NASDAQ: SGRY · Real-Time Price · USD
23.26
+1.10 (4.96%)
At close: May 12, 2025, 4:00 PM
23.43
+0.17 (0.73%)
After-hours: May 12, 2025, 7:57 PM EDT
Surgery Partners Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Surgery Partners stock have an average target of 35.43, with a low estimate of 28 and a high estimate of 43. The average target predicts an increase of 52.32% from the current stock price of 23.26.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Surgery Partners stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 3 | 3 | 3 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Benchmark | Benchmark | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +50.47% | Apr 21, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $35 | Buy | Reiterates | $35 | +50.47% | Mar 25, 2025 |
| Macquarie | Macquarie | Buy Maintains $34 → $33 | Buy | Maintains | $34 → $33 | +41.87% | Mar 11, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $38 → $28 | Hold | Maintains | $38 → $28 | +20.38% | Dec 3, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $49 → $35 | Buy | Maintains | $49 → $35 | +50.47% | Nov 20, 2024 |
Financial Forecast
Revenue This Year
3.45B
from 3.11B
Increased by 10.88%
Revenue Next Year
3.77B
from 3.45B
Increased by 9.21%
EPS This Year
1.03
from -1.33
EPS Next Year
1.37
from 1.03
Increased by 32.89%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.6B | 4.0B | 4.5B | ||
| Avg | 3.5B | 3.8B | 4.2B | ||
| Low | 3.3B | 3.6B | 3.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.2% | 16.9% | 20.0% | ||
| Avg | 10.9% | 9.2% | 11.3% | ||
| Low | 6.1% | 3.1% | 3.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.38 | 1.79 | 2.14 | ||
| Avg | 1.03 | 1.37 | 1.66 | ||
| Low | 0.48 | 0.81 | 1.17 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 72.9% | 56.1% | ||
| Avg | - | 32.9% | 21.0% | ||
| Low | - | -21.2% | -15.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.